Company profile
vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cadisegliatin | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02916056 | phase3 | terminated | 2016-12-01 | 2018-06-01 | vTv Therapeutics | 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) |
| NCT01474083 | phase1_2 | completed | 2011-11-01 | 2012-08-01 | vTv Therapeutics | A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes |
| NCT01548430 | phase1 | completed | 2011-10-01 | 2013-02-01 | vTv Therapeutics | A Safety Study of TTP4000 in Subjects With Alzheimer's Disease |
| NCT01665352 | phase2 | completed | 2012-08-01 | 2013-05-01 | vTv Therapeutics | A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes |
| NCT02653599 | phase2 | completed | 2015-12-01 | 2016-11-01 | vTv Therapeutics | A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes |
FDA applications (0)
No records yet.